Three Reasons Why Kybella is a Game Changer
Originally Published by Aesthetic Advancements
In the aesthetic world, the news of Kybella®’s FDA approval was unavoidable. Unlike Botox, which yields results that last for up to six months in as few as four days, Kybella® results are noticeable at four to six weeks and last for years, which means that once treatment outcomes are achieved, additional treatments shouldn’t be needed. The hype around the new treatment is so big that even mainstream TV took note:
Kathie Lee and Hoda watch plastic surgeon Dr. Brian Glatt perform a new FDA-approved treatment for neck fat, called Kybella, on two patients, live on TODAY.
The word is out to say the least. Here are three reasons Kybella represents an evolution in aesthetic enhancement:
1. New Treatment
So why not inject Kybella all over? As of right now, it’s indicated only for the submental fat (double chin). But stay tuned; a similar substance may be in the pipeline for use below the neck.
According to the website:
Kybella (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
In nearly every mention of what Kybella was approved for comes a quick reminder that Kybella is only approved for that specific region:
The safe and effective use of Kybella for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Once the cat is out of the bag, there is really no putting it back. Less ethical and legally minded aesthetic practitioners will start experimenting with Kybella® in other regions where liposuction isn’t an option. While the reviews have been great so far, we expect to see some headlines where people use these treatments off-label or poorly administer them and lawsuits will follow, like Botox. As long as practitioners are properly trained and stick to FDA guidelines, practices should experience an influx of…
2. New Clientele
According to a New York Post article:
“Forty percent of my [Kybella] patients are men. On some days, it’s even more men than women,” says Dr. Sachin Shridharani, an Upper East Side-based plastic surgeon who has treated 30 patients, including Kristian, with Kybella since its June 15 release. Typically, male patients make up less than 10 percent of his practice.
Men and other segments of people who wouldn’t consider aesthetic enhancements before Kybella are going to visit. With this new wave of people, patient selection will be more important than ever. Good outcomes can be a rising tide that raises all the ships, but a few bad outcomes can be enough to cast a shadow over everyone.
3. New Trend
Kybella represents a welcome change in the aesthetic industry. The treatment was approved and brought to market much faster than prior treatments. Aestheticians hope this a sign that innovation and regulations are accelerating. With new treatments on the horizon, practices should have more opportunities for growth.
Khloe Kardashian Kicks Off Kybella's Live Chin Up Campaign
March 3, 2016
Allergan, the maker of Botox, kicked off their Live Chin Up campaign at an exclusive event in New York City today, hosted by television personality and New York Times best-selling author Khloé Kardashian. The Live Chin Up campaign is designed to help encourage people to not let the things that bother them get in their way.
At the event, Kardashian moderated a distinguished panel of experts which included a dermatologist who discussed submental fullness and treatment options, including Kybella (deoxycholic acid) injection. Additionally, a patient joined the panel to discuss her experience with submental fullness.
"We are very pleased that Khloé was able to serve as the host of our event and discuss how she lives chin up," said Philippe Schaison, EVP and President of Allergan Medical. "As someone who lives life in the public eye, Khloé embodies what it means to live chin up by refusing to let negativity stand in her way. We feel she is the perfect person to kick off this inspiring campaign."